Lercanidipine Zentiva

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Zentiva, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lercanidipine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Zentiva is a calcium channel blocker indicated for the management of high blood pressure. - Hypertension: Lowers elevated blood pressure, helping to reduce the risk of cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of the ankles or feet. - Dizziness: especially upon standing. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or throat requiring urgent care. - Severe hypotension: marked drop in blood pressure causing faintness. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating therapy with Lercanidipine, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; observe liver enzymes. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Elderly patients: start at the lowest effective dose and titrate slowly. - Pregnancy: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lercanidipine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive hypotensive effect. - Diuretics: risk of excessive blood‑pressure reduction. - Grapefruit juice: can raise drug exposure and increase side‑effect risk.